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Poster Session II S287decreases overall survival. Several risk factors for graft failure have
been reported, such as reduced intensity conditioning, HLA-mis-
match, T-cell depleted grafts etc. However, in the early post-trans-
plant period following myeloablative conditioning there is a lack of
tools for early detection of patients at risk for subsequent graft fail-
ure. For this purpose, we retrospectively evaluated all patients who
after myeloablative conditioning received peripheral blood cells
(PBSC) at our centre during 1995 to 2007 (n5 219). The indications
for transplantation were: AML (43%), ALL (23%), CML (17%),
myelodysplastic syndrome (6%), lymphoma (5%), metabolic disor-
ders (4%), and multiple myeloma (2%). Graft failure was defined
as absolute neutrophil count (ANC)\0.5  109/L or less than 5%
donor cell chimerism. Moreover, primary graft failure was set to
day 28 post-transplant, and patients who died prior to that day
were excluded from further analyses. Three patients experienced
graft failure within 100 days post-transplant (2 primary and 1 sec-
ondary graft failure), which means that the incidence of graft failure
was 1.4%. In univariate analysis, there was a tendency that the total
nucleated cell dose was associated with primary graft failure
(P5 0.06). In contrast, when analyzing risk factors for graft failure
within 100 days post-transplant the total nucleated cell dose seemed
to be unimportant (P5 0.17). Interestingly, in subanalyses the risk of
graft failure within 100 days post-transplant was markedly increased
in those patients who still had an ANC less than 0.2 109/L at day 16
post-transplant (OR5 30, P\0.01). In conclusion, we suggest that
in patients with less than 0.2  109/L in ANC 16 days post-trans-
plant one must consider interventions to avoid subsequent graft fail-
ure. For this purpose, strategies such as administration of
hematopoietic growth factors (e.g. G-CSF) or donor lymphocyte in-
fusions need further evaluation.348
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Historically, allo-SCT using MM-URD has been associated
with poor outcomes, due primarily to high rates of GVHD. De-
creasing the rate of GVHD, without increasing relapse, should
lead to better outcomes and wider use of this life-saving proce-
dure. Between 6/1/05 and 9/30/09, 88 patients (pts) received a first
allo-SCT from an unrelated adult volunteer donor at Mayo Clinic
Arizona/Phoenix Children’s Hospital. This report focuses on the
subset of 69 pts transplanted for malignancy who received at least
one dose of Thymo (dose range 2.5-10 mg/kg, dependent on de-
gree of HLA mismatch) as part of their GVHD prophylactic reg-
imen (19 excluded, 9 with non-malignant disease, 10 who did not
receive Thymo due to MD preference). Forty-two pts were HLA-
identical (10/10) with their unrelated donor by high resolution
typing, while 27 were mismatched at one or more loci as follows:
1 allele mismatch (7); 1 antigen (Ag) mismatch (11); 2 allele mis-
match (2); 1 Ag and 1 allele mismatch (5); and 2 Ag mismatch (2).
The median age was 37 (0.5-75). Conditioning was ablative in 48,
reduced intensity in 21; graft source was PBSC in 47, marrow in
22. In addition to Thymo, all pts received a calcineurin inhibitor
(or sirolimus) plus methotrexate or MMF for GVHD prophylaxis.
The outcomes are shown in the Table. The estimated 2-yr overall
survival (OS) did not differ between the matched (61.1%) and mis-
matched pts (60.5%). The rates of aGVHD grades II-IV (48.6%
matched vs. 39.9% mismatched) and relapse (28.6% matched vs.
17.5% mismatched) also were not significantly different. Pts who
received mismatched marrow grafts had relatively poor outcomes
(2 yr OS 21.9%) due to increased relapse and higher than expected
NRM, which did not appear to be explained by higher disease risk.
By design, these pts received relatively high doses of Thymo (7.5-
10 mg/kg), and such high doses may have led to excessive T-cell
depletion of marrow grafts, abrogating the graft vs. malignancyeffect and leading to increased infectious mortality. In contrast,
pts receiving mismatched PBSC grafts (who received similar doses
of Thymo), had good outcomes (2 yr OS 91.5%) and low relapse
rates (2 yr rel 0%). We conclude that 1) using PBSC as graft
source and in vivo T-cell depletion, mismatched unrelated SCT
can be safely performed with excellent outcomes in adult and pe-
diatric pts with hematologic malignancy; and 2) modification of
the Thymo dose will be necessary to achieve similar success using
marrow grafts.
Outcomes by Match Grade and Graft Type
2 Yr 2 Yr aGVHD aGVHD
Match Grade Graft N OS Rel II-IV III-IVMatched Either 42 61.1% 28.6% 48.6% 8.3%
Matched PBSC 30 57.3% 30.4% 46.2% 8.1%
Matched Marrow 12 68.2% 25.4% 53.9% 8.8%Mismatched Either 27 60.5% 17.5% 39.9% 14.6%
Mismatched PBSC 17 91.5% 0.0% 41.8% 16.3%
Mismatched Marrow 10 21.9% 50.5% 37.1% 12.2%349
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Chimerism defines the amount of donor versus recipient hema-
topoiesis following allogeneic stem cell transplant (SCT). PCR-
based analyses of short tandem repeats (STRs) are commonly
used and are accurate and applicable to allogeneic transplant recip-
ients. These analyses are performed on peripheral blood and mar-
row aspirates, but it is not known if it is necessary to analyze both.
We performed a retrospective analysis of 42 consecutive adult allo-
geneic SCT recipients at our institution with available chimerism
studies. PCR and capillary electropheresis of microsatellite loci
were performed at 30, 60, and 90 days after SCT on both unfrac-
tionated blood and unfractionated marrow aspirate. Full donor chi-
merism (FDC) was defined as 95% or greater donor chimerism.
PCR analyses of STRs for chimerism performed on unfractionated
blood did not differ from results obtained on unfractionated mar-
row aspirate at 30, 60, or 90 days post transplant (P\0.0001). Pe-
ripheral blood PCR-based chimerism analyses provide similar
information as marrow aspirate analyses. Using peripheral blood
alone saves the expense of an additional analysis on marrow aspirate
and prevents an uncomfortable procedure. These findings provide
unique results suggesting larger studies in the adult population
are needed to further delineate the role of chimerism analyses
following allogeneic SCT.350
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Introduction: Allogeneic hematopoietic stem cell transplantation
(HSCT) is a curative treatment option for an expanding spectrum
of patients (pts) with a greater variety of diseases and graft sources,
cytoreductive regimens, cellular therapies, and supportive care.
